Galectin Therapeutics to Present at the American Association for the Study of Liver Disease Liver Meeting 2025 Life Science Investing
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor Pharmaceutical Investing
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives Pharmaceutical Investing
Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease Pharmaceutical Investing
